Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions

Monoclonal antibody induced infusion reactions (IRs) can be serious and even fatal. We used clinical data and blood samples from 37 treatment naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) initiating therapy for progressive disease with a single 50 mg dose of intra...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Leukemia research 2023-06, Vol.129, p.107072-107072, Article 107072
Hauptverfasser:	Moore, Jeremiah E., Bloom, Paige C., Chu, Charles C., Bruno, Jennifer E., Herne, Christine A., Baran, Andrea M., Quataert, Sally A., Mosmann, Timothy R., Taylor, Ronald P., Wallace, Danielle S., Elliott, Michael R., Barr, Paul M., Zent, Clive S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents - therapeutic use Chemokine CXCL10 - therapeutic use Chronic lymphocytic leukemia CXCL10 Cytokine release syndrome Cytokines First dose infusion reaction Gamma interferon Humans Interferon-gamma - therapeutic use IP-10 Leukemia, Lymphocytic, Chronic, B-Cell - pathology Rituximab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!